The Panel is the charitable gift at the center of the Program — a unitized hereditary cancer risk-assessment product, donated to qualifying public charities. Its analytical component is a laboratory-developed assay for inherited cancer-risk variants.
The Panel is one unitized 50-Gene Hereditary Cancer Risk Assessment Product consisting of the Collection Kit, the Included Logistics, and the associated one-time Panel Fulfillment Rights, intended to be acquired, owned, held, valued, and transferred together as one commercial unit. Its analytical component, the 50-Gene Assay, is a saliva-based laboratory-developed test that identifies certain inherited germline variants that may be associated with elevated risk for specified cancers. A Panel is not a medical or clinical service and does not screen for, detect, confirm, or diagnose active cancer or any other disease. It is not a medical or clinical service and does not screen for, detect, confirm, or diagnose active cancer or any other disease.
The Company’s role is to acquire and donate the Panel. The clinical activity — collection, administration, and follow-up with participants — is carried out by the charity’s clinical partner, under the direction of qualified medical professionals.
The Company donates Panels to a qualifying §501(c)(3) public charity.
The charity’s clinical partner proctors specimen collection under qualified medical direction.
A CLIA-certified laboratory analyzes the specimen and returns results to the clinical partner.
The clinical partner follows up with participants regarding their results.
See how the charitable gift of the Panel becomes an allocable deduction for Members.
How the program works →